Adaptimmune Therapeutics PLC splits its revenue into 5 lines in its filings. The largest line in fiscal 2024, which ended Dec 31, 2024 was Development Revenue at $176.8 million, 99% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Jun 30, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
65
|
178
|
60
|
27
|
6
|
4
|
1
|
60
|
38
|
14
|
| Development Revenue |
—
|
177
+193.3%
share 99.3%
|
60
+122.0%
share 100.0%
|
27
+341.5%
share 100.0%
|
6
+55.4%
share 100.0%
|
4
+252.8%
share 100.0%
|
1
-94.5%
share 100.0%
|
20
share 34.3%
|
—
|
—
|
| License Revenue |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
39
share 65.7%
|
—
|
—
|
| License And Service |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
39
share 65.7%
|
—
|
—
|
| Development And Service |
—
|
—
|
—
|
—
|
—
|
4
+252.8%
share 100.0%
|
1
-94.5%
share 100.0%
|
20
share 34.3%
|
—
|
—
|
| Product |
—
|
1
share 0.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADAPY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Abingdon, Oxfordshire
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1621227
- Former names
- Adaptimmune Ltd (until Mar 17, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.